Your browser doesn't support javascript.
loading
Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.
Glubb, Dylan M; Maranian, Mel J; Michailidou, Kyriaki; Pooley, Karen A; Meyer, Kerstin B; Kar, Siddhartha; Carlebur, Saskia; O'Reilly, Martin; Betts, Joshua A; Hillman, Kristine M; Kaufmann, Susanne; Beesley, Jonathan; Canisius, Sander; Hopper, John L; Southey, Melissa C; Tsimiklis, Helen; Apicella, Carmel; Schmidt, Marjanka K; Broeks, Annegien; Hogervorst, Frans B; van der Schoot, C Ellen; Muir, Kenneth; Lophatananon, Artitaya; Stewart-Brown, Sarah; Siriwanarangsan, Pornthep; Fasching, Peter A; Ruebner, Matthias; Ekici, Arif B; Beckmann, Matthias W; Peto, Julian; dos-Santos-Silva, Isabel; Fletcher, Olivia; Johnson, Nichola; Pharoah, Paul D P; Bolla, Manjeet K; Wang, Qin; Dennis, Joe; Sawyer, Elinor J; Tomlinson, Ian; Kerin, Michael J; Miller, Nicola; Burwinkel, Barbara; Marme, Frederik; Yang, Rongxi; Surowy, Harald; Guénel, Pascal; Truong, Thérèse; Menegaux, Florence; Sanchez, Marie; Bojesen, Stig E.
Afiliação
  • Glubb DM; Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia.
  • Maranian MJ; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK.
  • Michailidou K; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.
  • Pooley KA; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK.
  • Meyer KB; Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
  • Kar S; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.
  • Carlebur S; Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
  • O'Reilly M; Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
  • Betts JA; Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia; School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD 4072, Australia.
  • Hillman KM; Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia.
  • Kaufmann S; Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia.
  • Beesley J; Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia.
  • Canisius S; Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
  • Hopper JL; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC 3010, Australia.
  • Southey MC; Department of Pathology, University of Melbourne, Melbourne, VIC 3010, Australia.
  • Tsimiklis H; Department of Pathology, University of Melbourne, Melbourne, VIC 3010, Australia.
  • Apicella C; Department of Pathology, University of Melbourne, Melbourne, VIC 3010, Australia.
  • Schmidt MK; Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
  • Broeks A; Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
  • Hogervorst FB; Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands.
  • van der Schoot CE; Sanquin Research, 1066 CX Amsterdam, the Netherlands.
  • Muir K; Division of Health Sciences, Warwick Medical School, Warwick University, Coventry CV4 7AL, UK; Institute of Population Health, University of Manchester, Manchester M13 9PL, UK.
  • Lophatananon A; Division of Health Sciences, Warwick Medical School, Warwick University, Coventry CV4 7AL, UK.
  • Stewart-Brown S; Division of Health Sciences, Warwick Medical School, Warwick University, Coventry CV4 7AL, UK.
  • Siriwanarangsan P; Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Fasching PA; University Breast Center Franconia, Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany; Division of Hematology and Oncology, Department of Medicine, David Geffe
  • Ruebner M; University Breast Center Franconia, Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany.
  • Ekici AB; Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany.
  • Beckmann MW; University Breast Center Franconia, Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany.
  • Peto J; Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
  • dos-Santos-Silva I; Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
  • Fletcher O; Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK.
  • Johnson N; Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK.
  • Pharoah PD; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.
  • Bolla MK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.
  • Wang Q; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.
  • Dennis J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.
  • Sawyer EJ; Research Oncology, Division of Cancer Studies, King's College London, Guy's Hospital, London SE1 9RT, UK.
  • Tomlinson I; Wellcome Trust Centre for Human Genetics and Oxford Biomedical Research Centre, University of Oxford OX3 7BN, UK.
  • Kerin MJ; Clinical Science Institute, University Hospital Galway, Galway, Ireland.
  • Miller N; Clinical Science Institute, University Hospital Galway, Galway, Ireland.
  • Burwinkel B; Department of Obstetrics and Gynecology, University of Heidelberg, 69115 Heidelberg, Germany.
  • Marme F; Department of Obstetrics and Gynecology, University of Heidelberg, 69115 Heidelberg, Germany; National Center for Tumor Diseases, University of Heidelberg, 69120 Heidelberg, Germany.
  • Yang R; Department of Obstetrics and Gynecology, University of Heidelberg, 69115 Heidelberg, Germany; Molecular Genetics of Breast Cancer, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Surowy H; Department of Obstetrics and Gynecology, University of Heidelberg, 69115 Heidelberg, Germany; Molecular Genetics of Breast Cancer, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Guénel P; Institut National de la Santé et de la Recherche Médicale U1018, Environmental Epidemiology of Cancers, Centre de Recherche en Epidémiologie et Santé des Populations, 94807 Villejuif, France; UMRS 1018, University Paris-Sud, 94807 Villejuif, France.
  • Truong T; Institut National de la Santé et de la Recherche Médicale U1018, Environmental Epidemiology of Cancers, Centre de Recherche en Epidémiologie et Santé des Populations, 94807 Villejuif, France; UMRS 1018, University Paris-Sud, 94807 Villejuif, France.
  • Menegaux F; Institut National de la Santé et de la Recherche Médicale U1018, Environmental Epidemiology of Cancers, Centre de Recherche en Epidémiologie et Santé des Populations, 94807 Villejuif, France; UMRS 1018, University Paris-Sud, 94807 Villejuif, France.
  • Sanchez M; Institut National de la Santé et de la Recherche Médicale U1018, Environmental Epidemiology of Cancers, Centre de Recherche en Epidémiologie et Santé des Populations, 94807 Villejuif, France; UMRS 1018, University Paris-Sud, 94807 Villejuif, France.
  • Bojesen SE; Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark; Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, D
Am J Hum Genet ; 96(1): 5-20, 2015 Jan 08.
Article em En | MEDLINE | ID: mdl-25529635
ABSTRACT
Genome-wide association studies (GWASs) have revealed SNP rs889312 on 5q11.2 to be associated with breast cancer risk in women of European ancestry. In an attempt to identify the biologically relevant variants, we analyzed 909 genetic variants across 5q11.2 in 103,991 breast cancer individuals and control individuals from 52 studies in the Breast Cancer Association Consortium. Multiple logistic regression analyses identified three independent risk signals the strongest associations were with 15 correlated variants (iCHAV1), where the minor allele of the best candidate, rs62355902, associated with significantly increased risks of both estrogen-receptor-positive (ER(+) odds ratio [OR] = 1.24, 95% confidence interval [CI] = 1.21-1.27, ptrend = 5.7 × 10(-44)) and estrogen-receptor-negative (ER(-) OR = 1.10, 95% CI = 1.05-1.15, ptrend = 3.0 × 10(-4)) tumors. After adjustment for rs62355902, we found evidence of association of a further 173 variants (iCHAV2) containing three subsets with a range of effects (the strongest was rs113317823 [pcond = 1.61 × 10(-5)]) and five variants composing iCHAV3 (lead rs11949391; ER(+) OR = 0.90, 95% CI = 0.87-0.93, pcond = 1.4 × 10(-4)). Twenty-six percent of the prioritized candidate variants coincided with four putative regulatory elements that interact with the MAP3K1 promoter through chromatin looping and affect MAP3K1 promoter activity. Functional analysis indicated that the cancer risk alleles of four candidates (rs74345699 and rs62355900 [iCHAV1], rs16886397 [iCHAV2a], and rs17432750 [iCHAV3]) increased MAP3K1 transcriptional activity. Chromatin immunoprecipitation analysis revealed diminished GATA3 binding to the minor (cancer-protective) allele of rs17432750, indicating a mechanism for its action. We propose that the cancer risk alleles act to increase MAP3K1 expression in vivo and might promote breast cancer cell survival.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromossomos Humanos Par 5 / Neoplasias da Mama / Mapeamento Cromossômico / Locos de Características Quantitativas / MAP Quinase Quinase Quinase 1 Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Am J Hum Genet Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromossomos Humanos Par 5 / Neoplasias da Mama / Mapeamento Cromossômico / Locos de Características Quantitativas / MAP Quinase Quinase Quinase 1 Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Am J Hum Genet Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Austrália